



Joint BioRN & Ci3 Annual Conference 2018

Immunotherapy and beyond - The next generation of cancer treatment

October 25th, 2018 hosted by Merck in Darmstadt



- AGENDA -

Moderation: André Domin, Technology Park Heidelberg

08:30 – 09:15 REGISTRATION AND GET-TOGETHER

09:15 – 10:05 WELCOME AND INTRODUCTION

09:15 – 09:30 **Welcome from the Organizers**
Board members of BioRN and Ci3

09:30 – 09:35 **Welcome from the Host**
Ulrich Betz, Merck

09:35 – 09:50 **Recent Breakthroughs from Merck's Biopharma R&D**
Luciano Rossetti, Merck

09:50 – 10:05 **Health Axis Europe Partnering –
A Joint Project for Tailored Innovation Scouting**
Julia Schafft, BioRN

10:05 – 10:55 THERAPEUTIC VACCINATION

10:05 – 10:35 **KEYNOTE: Individualized Cancer Immunotherapy**
Ugur Sahin, BioNTech/TRON

10:35 – 10:55 **Tumor Antigen-Loaded Natural Dendritic Cells:
A More Powerful Next Generation Cancer Vaccine?**
Gerty Schreibelt, Radboudumc

10:55 – 11:25 COFFEE BREAK & POSTER SESSION

11:25 – 12:25	CELLULAR THERAPIES
11:25 – 11:45	Receptor-Targeted Viral Vectors in Immunotherapy Christian Buchholz, Paul-Ehrlich-Institut
11:45 – 12:05	CAR-Engineered NK Cells: Off-the-Shelf Therapeutics Bridging Innate and Adaptive Immunity Winfried Wels, Georg-Speyer-Haus
12:05 – 12:25	Challenges in CAR-T Manufacturing Andrea Schilz, BioNTech IMFS
12:25 – 13:25	COMBINATION THERAPIES
12:25 – 12:45	Combinations and/or Bi-Functional Molecules as Next Generation IO Therapies Jörn-Peter Halle, Merck
12:45 – 13:05	Intelligent Combination Treatment Dirk Jäger, National Center for Tumor Diseases
13:05 – 13:25	Therapeutic Strategies Based on Innate Immunity and Affimed's ROCK® Platform Martin Treder, Affimed
13:25 – 14:55	LUNCH BREAK & POSTER SESSION
14:55 – 16:05	NOVEL TARGETS AND AGENTS
14:55 – 15:15	Apogenix' TNFR-Mediated Signaling Modulators – Innovative Immuno-Oncology Therapeutics Thomas Höger, Apogenix
15:15 – 15:35	Development of First-In-Class Immuno-Oncology Drugs in the Context of the DKFZ-Bayer Alliance Rienk Offringa, German Cancer Research Center
15:35 – 16:05	KEYNOTE: Future Innovation in Cancer Therapeutics – An AbbVie Oncology Perspective Neil Gallagher, AbbVie
16:05 – 16:30	WRAP-UP
16:05 – 16:30	Wrap-Up and Closing Remarks Board members of BioRN and Ci3 together with Ulrich Betz, Merck
16:30 – 17:30	GET-TOGETHER & POSTER SESSION